

COVID-19 Vaccine Product – Quick Reference Guide

The following information is a summary of vaccine products and does not reflect current vaccine eligibility, for additional information please refer to the current [Ontario Ministry of Health Guidance](#) and individual [product monographs](#).

Please note: the columns for Nuvaxovax (Novavax) and Janssen (Johnson and Johnson) have been removed from this table for space reasons. These vaccines should only be used in exceptional cases but remain available. Detailed information continues to be found in the previously referenced Ontario Ministry of Health COVID-19 Vaccine Guidance. The column for Covifenz (Medicago) has been removed since this vaccine is no longer available in Ontario.

COVID-19 Vaccine Product Name	COMIRNATY (Pfizer-BioNTech)	COMIRNATY (Pfizer-BioNTech)	COMIRNATY (Pfizer-BioNTech)	COMIRNATY (Pfizer-BioNTech)	SPIKEVAX (Moderna)	SPIKEVAX Bivalent (Moderna)	COMIRNATY Bivalent (Pfizer-BioNTech)
Physical Details of vial:	Maroon cap/label border	Orange cap/label border	Purple cap/label border	Gray cap/label border	Red cap, light blue label– 0.20 mg/mL Blue Cap, purple label– 0.10 mg/mL (hence the alternating colour coding)	royal blue cap and green label	Gray cap/gray label border <u>AND</u> product name states <u>bivalent</u> .
Type	mRNA – monovalent	mRNA – monovalent	mRNA - monovalent	mRNA - monovalent	mRNA - monovalent	mRNA - bivalent	mRNA - bivalent
Authorized age for use	6 months to < 5 years	5 to 11 years of age * see provincial guidance for preferred vaccine based on age and previous vaccine doses	≥12 years of age	≥12 years of age	≥ 6 months of age * see provincial guidance for preferred vaccine based on age and previous vaccine doses	≥ 18 years of age	≥12 years of age
Dose/Route	3 mcg (0.2 mL)	10 mcg (0.2 mL, IM)	30 mcg (0.3 mL, IM)	30 mcg (0.3 mL IM)	Note: Moderna monovalent vaccine is now available in two different concentrations <u>Aged 6 months to 5 years: primary series should be obtained from the blue cap (0.10 mg/mL) vial only</u> 25 mcg, IM or 0.25 mL (blue cap)	50 mcg (0.5 mL IM)	30 mcg (0.3 mL)

Please note the information in this table is current as of the date listed as last updated, and is subject to change. Please refer to product monographs and current Ontario Ministry of Health Guidance for current COVID-19 vaccine information.

					<p><u>Aged 6-11: primary series can be obtained from the blue cap (0.10 mg/mL) or red cap (0.20 mg/mL) vial:</u> 50 mcg, IM or 0.50 mL (blue cap) 50 mcg, IM or 0.25 mL (red cap)</p> <p><u>12+ years of age: primary series should be obtained from the red cap (0.20 mg/mL) vial only</u> 100 mcg, IM or 0.50 mL (red cap)</p>		
Format	Multi-dose vial: 10 dose vials	Multi-dose vial: 10 dose vials	Multi-dose vial: 6 dose vials	Multi-dose vial: 6 dose vials	Multi-dose vial (actual number of dose depends on volume extracted) : Red cap – 0.20 mg/mL Blue Cap – 0.10 mg/mL	Multi-dose vial: 5 doses	Multi-dose vial: 6 doses per vial
Dilute	Yes Each vial diluted with 2.2 mL 0.9% sodium chloride injection USP. See product monograph for more Information	Yes Each vial diluted with 1.3 mL 0.9% sodium chloride injection USP. See product monograph for more Information	Yes Each vial diluted with 1.8 mL 0.9% sodium chloride injection USP. See product monograph for more information	No DO NOT DILUTE	No	No	No DO NOT DILUTE
Potential allergen <i>*any component of the vaccine could be a potential allergen</i>	Polyethylene glycol (PEG) Tromethamine (Tromethamol or Tris)	Polyethylene glycol (PEG) Tromethamine (Tromethamol or Tris)	Polyethylene glycol (PEG)	Polyethylene glycol (PEG) Tromethamine (Tromethamol or Tris)	Polyethylene glycol (PEG) Tromethamine (Tromethamol or Tris)	Polyethylene glycol (PEG) Tromethamine (Tromethamol or Tris)	Polyethylene glycol (PEG) Tromethamine (Tromethamol or Tris)
Storage: Pre puncture (for storage at frozen state, please see product monograph)	10 weeks at 2°C to 8°C Vaccine is stable at room temperature (8°C to 25°C) for no	10 weeks at 2°C to 8°C Vaccine is stable at room temperature (8°C to 25°C) for no more than 12 hours	1 month (31 days) at 2°C to 8°C Vaccine is stable at room temperature	10 weeks at 2°C to 8°C Vaccine is stable at room temperature (8°C to 25°C) for no more	30 days at 2°C to 8°C 24 hours at room temperature (8°C to 25°C)	30 days at 2°C to 8°C 24 hours at room temperature (8°C to 25°C)	10 weeks at 2°C to 8°C Vaccine is stable at room temperature (8°C to 25°C) for no more than 12 hours prior to first

Please note the information in this table is current as of the date listed as last updated, and is subject to change. Please refer to product monographs and current Ontario Ministry of Health Guidance for current COVID-19 vaccine information.

	more than 12 hours prior to first puncture (including any thaw time)	prior to first puncture (including any thaw time)	(8°C to 25°C) for no more than 2 hours (including any thaw time)	than 12 hours prior to first puncture (including any thaw time)			puncture (including any thaw time)
Storage: Post Puncture	Discard after 12 hours Can be stored between 2°C to 25°C	Discard after 12 hours Can be stored between 2°C to 25°C	Discard after 6 hours Can be stored between 2°C to 25°C	Discard after 12 hours Can be stored between 2°C to 25°C	24 hours Can be stored between 2°C to 25°C Regardless of puncture, Moderna vaccine can only be stored at room temperature (8°C to 25°C) for a total of 24 hours. Any time spent between (8°C to 25°C) should be tracked and not exceed 24 hours cumulatively Each Moderna monovalent vial has puncture limits: Red cap – 20 puncture limit Blue cap – 10 puncture limit	24 hours Can be stored between 2°C to 25°C Regardless of puncture, Moderna vaccine can only be stored at room temperature (8°C to 25°C) for a total of 24 hours. Any time spent between (8°C to 25°C) should be tracked and not exceed 24 hours cumulatively	Discard after 12 hours Can be stored between 2°C to 25°
Product Monograph (Health Canada)	https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-pm1-en.pdf	https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-pm1-en.pdf	https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-pm1-en.pdf	https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-pm1-en.pdf	https://covid-vaccine.canada.ca/info/pdf/covid-19-vaccine-moderna-pm-en.pdf	https://covid-vaccine.canada.ca/info/pdf/spi-kevax-bivalent-en.pdf	https://covid-vaccine.canada.ca/info/pdf/covid-19-vaccine-mirnaty-original-omicron-ba4ba5-pm-en.pdf

Please note the information in this table is current as of the date listed as last updated, and is subject to change. Please refer to product monographs and current Ontario Ministry of Health Guidance for current COVID-19 vaccine information.